Thyroid Hormone Augmentation for Bipolar Disorder: A Systematic Review.
Level 1 - systematic review of randomized trials
Systematic review including randomized controlled trials
PubMed 36421864 · doi:10.3390/brainsci12111540
What was done
A systematic review was conducted following PRISMA guidelines across Ovid MEDLINE, Embase, PsycINFO, and Cochrane databases for randomized controlled trials, open-label trials, and observational studies of levothyroxine (LT4) and triiodothyronine (T3) augmentation in bipolar disorder. Eight studies were included.
What was found
The abstract reports no numerical data, effect sizes, or confidence intervals. Open-label trials of high-dose LT4 reported improved depression outcomes in bipolar depression and reduced recurrence in rapid cycling. However, one randomized controlled trial (RCT) of high-dose LT4 showed no benefit compared with placebo, and another RCT comparing LT4, T3, and placebo demonstrated benefit only in rapid-cycling bipolar women. Available data for T3 were limited. No significant thyrotoxicosis was reported across studies. Meta-analysis could not be completed due to heterogeneity in study designs, interventions, and outcome measures.
Why it matters
While open-label studies suggested promise for supratherapeutic levothyroxine in bipolar disorder, randomized controlled trials have not consistently confirmed efficacy, indicating it should remain reserved for highly treatment-resistant presentations.
Limits
The evidence base is small (only eight studies), heterogeneous across interventions and patient subgroups, and dominated by lower-quality open-label designs. No meta-analytic pooling was possible, and the abstract provides no specific quantitative metrics or sample sizes.
Cited by
- context Functional psychiatry uses T3 to treat conditions like manic depression and schizophrenia due to T3 receptor sites in the brain.